Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Halts The TIDE Of New Avandia Patients; Informed Consent Changes Loom

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency's partial clinical hold prevents new subjects from enrolling in GlaxoSmithKline's postmarketing safety study of rosiglitazone and suggests informed consent process for current subjects be revised to reflect advisory committee deliberations on the drug's safety.

You may also be interested in...



FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk

Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.

FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk

Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.

Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says

FDA used the Avandia advisory committee to defend its view that marketing withdrawal decisions can be based on safety comparisons to other drugs approved for the same condition

Related Content

Topics

UsernamePublicRestriction

Register

PS070937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel